2021
DOI: 10.1016/j.jtumed.2020.10.017
|View full text |Cite
|
Sign up to set email alerts
|

Letrozole and zoledronic acid changed signalling pathways involved in the apoptosis of breast cancer cells

Abstract: Objectives Oestrogen plays a key role in the development of breast malignancies. Therefore, aromatase inhibitors (e.g. letrozole [LTZ]) are widely used in the treatment of breast cancer. On the other hand, oestrogen is important to the integrity of bone mass. Research has shown that zoledronic acid (ZLA) may prevent osteoporosis. Therefore, the present research aims to investigate the effect of a combination of LTZ and ZLA in the treatment of breast cancer and in reducing osteoporosis in patients … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 33 publications
(21 reference statements)
0
1
0
Order By: Relevance
“…However, recent evidence has shown that ZA is able to modulate signaling pathways involved in apoptosis and that could be beneficial to be used together with letrozole to treat EsR-positive BC patients (198).…”
Section: Zoledronatementioning
confidence: 99%
“…However, recent evidence has shown that ZA is able to modulate signaling pathways involved in apoptosis and that could be beneficial to be used together with letrozole to treat EsR-positive BC patients (198).…”
Section: Zoledronatementioning
confidence: 99%